Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2025 USD ($) $ / shares	Mar. 31, 2025 USD ($) shares	Dec. 31, 2025 USD ($) program member $ / shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) program shares	Dec. 31, 2021 USD ($) program shares	Dec. 31, 2020 USD ($) shares
Related Party Transaction [Line Items]
Issuance of common stock			$ 429.0	$ 228.0	$ 25.0
Sale of stock, consideration received on transaction	$ 288.0	$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program					4
Licensing revenue recognized			240.0	243.0	$ 108.0
Accounts payable, current	42.0		42.0	18.0
Receivable from collaboration partners, current	$ 11.0		$ 11.0	20.0
Gilead
Related Party Transaction [Line Items]
Sale of stock, number of shares acquired in transaction (in shares) | shares		1.4
Sale of stock, consideration received on transaction		$ 15.0
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held	25.10%		25.10%
Accounts payable, current	$ 24.0		$ 24.0	0.0
Receivable from collaboration partners, current	$ 0.0		0.0	6.0
Related Party | Research and Development
Related Party Transaction [Line Items]
Reimbursement from related party for shared costs			$ 30.0	$ (37.0)	$ (110.0)
Common Stock Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Issuance of common stock (in shares) | shares				15.2	1.0	5.7	6.0
Funds received for stock purchase agreement				$ 320.0			$ 200.0
Purchase price of common stock allocation to performance obligation				87.0			$ 91.0
Issuance of common stock					$ 20.0	$ 220.0
Percentage of premium purchase price of common stock			20.00%
Trailing days average closing price			5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares	$ 33.54		$ 33.54
Number of board members | member			3
Common Stock Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage	35.00%		35.00%
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities			$ 60.0
Option payment upon achievement of certain development milestones			$ 150.0
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs							10 years
Option continuation payment due upon second anniversary of agreement							$ 100.0
Option continuation payment due upon sixth anniversary of agreement							100.0
Option continuation payment due upon fourth anniversary of agreement				100.0			100.0
Option continuation payment due upon eighth anniversary of agreement							100.0
Upfront cash payment							$ 175.0
Option fee per program for all other programs entering clinical development to exercise option						150.0
Number of research programs | program			2
Licensing revenue recognized			$ 240.0	$ 243.0	112.0
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab						$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | program						3
Option payments received						$ 725.0
Removal of option continuation payment under agreement						$ 100.0
Option payment upon achievement of certain development milestones					$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program					2,000,000
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment					$ 17.5
Number of research programs | program					2
Option payment upon completion of certain IND-enabling activities					$ 45.0
Total upfront cash payment					35.0
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received					$ 375.0